Cuban HB Vaccine in Clinical Trials

Cuban HB Vaccine in Clinical TrialsCuban HB Vaccine in Clinical Trials

A new Cuban vaccine for Hepatitis B is undergoing clinical trials in Australia, New Zealand, South Korea, Singapore, China, the Philippines and Thailand, apart from Cuba, said Iris Lugo, a specialist from the Center for Genetic Engineering and Biotechnology (CIGB), which developed the vaccine, Xinhua reported.

The vaccine, HeberNasvac, prevents the progression of the disease or keeps it under control for a longer time and causes fewer adverse reactions. The treatment period is shorter, not exceeding 20 weeks.

Moreover, clinical trials have shown that the vaccine has greater antiviral efficacy than conventional drugs. The drug is soon expected to obtain the permit granted by the Center for State Control of Drugs and Medical Devices, allowing it to be used in Cuba in 2016, Lugo said.

According to the World Health Organization, one million people die each year from diseases related to the Hepatitis B virus, which also is the main risk factor for liver cancer.